Inhibition of FK506 binding proteins reduces α-synuclein aggregation and Parkinson's disease-like pathology

Journal of Neuroscience

Volumn 30, Issue 7, 2010, Pages 2454-2463

  Gerard, Melanie ^a,b   Deleersnijder, Angélique ^a   Daniëls, Veronique ^a   Schreurs, Sarah ^a   Munck, Sebastian ^a   Reumers, Veerle ^a   Pottel, Hans ^a   Engelborghs, Yves ^a   Van Den Haute, Chris ^a   Taymans, Jean Marc ^a   Debyser, Zeger ^a,b   Baekelandt, Veerle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; FK 506 BINDING PROTEIN 52; TACROLIMUS; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

AGE FACTORS; ANIMALS; APOPTOSIS; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; INTERMEDIATE FILAMENT PROTEINS; LUCIFERASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NERVE DEGENERATION; NEUROBLASTOMA; PARKINSON DISEASE; RNA, SMALL INTERFERING; TACROLIMUS BINDING PROTEIN 1A; TACROLIMUS BINDING PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 77249126934     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5983-09.2010     Document Type: Article

References (61)

1. Avramut M, Achim CL (2002) Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav 77:463-468.
2. Avramut M, Zeevi A, Achim CL (2001) The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. Brain Res Dev Brain Res 132:151-157.
3. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A 102:1430-1435.
4. Brecht S, Schwarze K, Waetzig V, Christner C, Heiland S, Fischer G, Sartor K, Herdegen T (2003) Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain. Neuroscience 120:1037-1048.
5. Charters AR, Kobayashi M, Butcher SP (1994a) Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. Biochem Soc Trans 22:411S.
6. Charters AR, Kobayashi M, Butcher SP (1994b) The subcellular distribution of FK506 binding proteins in rat brain. Biochem Soc Trans 22:412S.
7. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169.
8. Coss MC, Stephens RM, Morrison DK, Winterstein D, Smith LM, Simek SL (1998) The immunophilin FKBP65 forms an association with the serine/threonine kinase c-Raf-1. Cell Growth Differ 9:41-48.
9. Davies TH, Ning YM, Sánchez ER (2005) Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 44:2030-2038.
10. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41:10209-10217.
11. Edlich F, Weiwad M, Wildemann D, Jarczowski F, Kilka S, Moutty MC, Jahreis G, Lücke C, Schmidt W, Striggow F, Fischer G (2006) The specific FKBP38 inhibitor N-(N′,N′- dimethylcarboxamidomethyl)cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J Biol Chem 281:14961-14970.
12. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404:394-398.
13. Freichel C, Neumann M, Ballard T, Müller V, Woolley M, Ozmen L, Borroni E, Kretzschmar HA, Haass C, Spooren W, Kahle PJ (2007) Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 28:1421-1435.
14. Galat A (2003) Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 3:1315-1347.
15. Gasser T (2009) Genomic and proteomic biomarkers for Parkinson disease. Neurology 72:S27-S31.
16. Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R (2005) Up-scaling of lentiviral vector production by tangential flow filtration. J Gene Med 7:1299-1310.
17. Gerard M, Debyser Z, Desender L, Kahle PJ, Baert J, Baekelandt V, Engelborghs Y (2006) The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J 20:524-526.
18. Gerard M, Debyser Z, Desender L, Baert J, Brandt I, Baekelandt V, Engelborghs Y (2008) FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T. J Neurochem 106:121-133.
19. Gold BG, Zeleny-Pooley M, Wang MS, Chaturvedi P, Armistead DM (1997) A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol 147:269-278.
20. Gold BG, Densmore V, Shou W, Matzuk MM, Gordon HS (1999) Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther 289:1202-1210.
21. Gold BG, Udina E, Bourdette D, Navarro X (2004) Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurol Res 26:371-380.
22. Göthel SF, Marahiel MA (1999) Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 55:423-436.
23. Guo X, Dawson VL, Dawson TM (2001) Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 13:1683-1693.
24. Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M (2005) Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci U S A 102:15871-15876.
25. Heise H, Celej MS, Becker S, Riedel D, Pelah A, Kumar A, Jovin TM, Baldus M (2008) Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant α-Synuclein. J Mol Biol 380:444-450.
26. Howard BR, Vajdos FF, Li S, Sundquist WI, Hill CP (2003) Structural insights into the catalytic mechanism of cyclophilin A. Nat Struct Biol 10:475-481.
27. Hoyer W, Cherny D, Subramaniam V, Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43:16233-16242.
28. Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364:1169-1171.
29. Kato H, Oikawa T, Otsuka K, Takahashi A, Itoyama Y (2000) Postischemic changes in the immunophilin FKBP12 in the rat brain. Brain Res Mol Brain Res 84:58-66.
30. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22:2780-2791.
31. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH (2009) α-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211-10222.
32. Labrande C, Velly L, Canolle B, Guillet B, Masmejean F, Nieoullon A, Pisano P (2006) Neuroprotective effects of tacrolimus (FK506) in a model of ischemic cortical cell cultures: role of glutamate uptake and FK506 binding protein 12 kDa. Neuroscience 137:231-239.
33. Lakso M, Vartiainen S, Moilanen AM, Sirvi ö J, Thomas JH, Nass R, Blakely RD, Wong G (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86:165-172.
34. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 13:364-372.
35. Lauwers E, Bequé D, Van Laere K, Nuyts J, Bormans G, Mortelmans L, Casteels C, Vercammen L, Bockstael O, Nuttin B, Debyser Z, Baekelandt V (2007) Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging 28:248-257.
36. Liu D, McIlvain HB, Fennell M, Dunlop J, Wood A, Zaleska MM, Graziani EI, Pong K (2007) Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells. J Neurosci Methods 163:310-320.
37. Murakami Y, Takamatsu H, Noda A, Osoda K, Ichise R, Tatsumi M, Tabata K, Sawamoto T, Nishimura S (2004) Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. J Nucl Med 45:1946-1949.
38. Nilsson A, Sköld K, Sjögren B, Svensson M, Pierson J, Zhang X, Caprioli RM, Buijs J, Persson B, Svenningsson P, Andrén PE (2007) Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinson's disease and identification of FKBP-12-binding proteins. J Proteome Res 6:3952-3961.
39. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054.
40. Pahlke D, Freund C, Leitner D, Labudde D (2005) Statistically significant dependence of the Xaa-Pro peptide bond conformation on secondary structure and amino acid sequence. BMC Struct Biol 5:8.
41. Pal D, Chakrabarti P (1999) Cis peptide bonds in proteins: residues involved, their conformations, interactions and locations. J Mol Biol 294:271-288.
42. Patterson CE, Schaub T, Coleman EJ, Davis EC (2000) Developmental regulation of FKBP65. An ER-localized extracellular matrix binding-protein. Mol Biol Cell 11:3925-3935.
43. Pong K, Zaleska MM (2003) Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord 2:349-356.
44. Poulter MO, Payne KB, Steiner JP (2004) Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 128:1-6.
45. Rulten SL, Kinloch RA, Tateossian H, Robinson C, Gettins L, Kay JE (2006) The human FK506-binding proteins: characterization of human FKBP19. Mamm Genome 17:322-331.
46. Sakai M, Hobara N, Hokama N, Kameya H, Ohshiro S, Sakanashi M, Saitoh H (2004) Increased bioavailability of tacrolimus after rectal administration in rats. Biol Pharm Bull 27:1480-1482.
47. Sheehan J, Eischeid A, Saunders R, Pouratian N (2006) Potentiation of neurite outgrowth and reduction of apoptosis by immunosuppressive agents: implications for neuronal injury and transplantation. Neurosurg Focus 20:E9.
48. Shirane M, Nakayama KI (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 5:28-37.
49. Sommer DB, Stacy MA (2008) What's in the pipeline for the treatment of Parkinson's disease? Expert Rev Neurother 8:1829-1839.
50. Steiner JP, Dawson TM, Fotuhi M, Glatt CE, Snowman AM, Cohen N, Snyder SH (1992) High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 358:584-587.
51. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo H, Connolly MA, Liang S, Ramsey C, Li JH, Huang W, Howorth P, Soni R, Fuller M, Sauer H, Nowotnik AC, Suzdak PD (1997) Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci U S A 94:2019-2024.
52. Stewart DE, Sarkar A, Wampler JE (1990) Occurrence and role of cis peptide bonds in protein structures. J Mol Biol 214:253-260.
53. Surguchov A (2008) Molecular cell biology of synucleins. In: International review of cell and molecular biology, Chap 6 (Kwang WJ, ed), pp 225-317. San Diego: Academic.
54. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, Wilson JM, Debyser Z, Baekelandt V (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 inmouse brain.Hum Gene Ther 18:195-206.
55. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Göttlinger HG (1994) Functional association of cyclophilin A with HIV-1 virions. Nature 372:363-365.
56. Tolosa E, Gaig C, Santamaría J, Compta Y (2009) Diagnosis and the premotor phase of Parkinson disease. Neurology 72:S12-S20.
57. Ulrih NP, Barry CH, Fink AL (2008) Impact of Tyr to Ala mutations on α-synuclein fibrillation and structural properties. Biochim Biophys Acta 1782:581-585.
58. Van den Haute C, Eggermont K, Nuttin B, Debyser Z, Baekelandt V (2003) Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum Gene Ther 14:1799-1807.
59. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819.
60. Volles MJ, Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41:4595-4602.
61. Woods WS, Boettcher JM, Zhou DH, Kloepper KD, Hartman KL, Ladror DT, Qi Z, Rienstra CM, George JM (2007) Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J Biol Chem 282:34555-34567.